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Abstract objective The risk of stroke rises after episodes of herpes zoster and chickenpox, which are caused
by varicella zoster virus (VZV). We conducted a pilot case–control study of stroke, nested within a
long-standing cohort in Uganda (the General Population Cohort), to examine antibodies against VZV
prior to diagnosis.
methods We used stored sera to examine the evolution of IgG and IgM antibodies against VZV
among 31 clinically confirmed cases of stroke and 132 matched controls. For each participant, three
samples of sera were identified: one each, taken at or near the time of (pseudo)diagnosis, between 5
and 10 years prior to diagnosis and at 15 years prior to diagnosis.
results All participants had detectable antibodies against VZV, but there were no significant
differences between cases and controls in the 15 years prior to diagnosis. As a secondary finding,
16% (5/31) of cases and 6% (8/132) of controls had HIV (OR 3.0; 95% CI 0.8–10.1; P = 0.06).
conclusions This is the first prospective study to examine a biological measure of exposure to
VZV prior to diagnosis of stroke and although we identified no significant association, in this small
pilot, with limited characterisation of cases, we cannot exclude the possibility that the virus is causal
for a subset. The impact of HIV on risk of stroke has not been well characterised and warrants
further study.
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Introduction
Varicella zoster virus (VZV) is a ubiquitous human her-
pes virus that, after primary infection (usually in child-
hood), causes chickenpox. It then persists
asymptomatically (latently) in the sensory ganglia of the
nervous system. Reactivation later in life and transloca-
tion via sensory nerve endings to the skin where it repli-
cates is associated with the skin lesion, herpes zoster
(shingles). VZV is the only human herpes virus that is
transmitted via the respiratory route, and the prevalence
in African populations exceeds 90% [1].
Both ischaemic and haemorrhagic strokes have been
described at autopsy after herpes zoster. Among these
cases, viral inclusions, DNA and antigen are present in
cerebral arteries, confirming the association between
VZV vasculopathy and stroke [2, 3]. Furthermore,
population-based studies indicate substantial increases in
risk of stroke, especially among younger people, after
reports of both herpes zoster and chickenpox [4–8]. This
raises the possibility that VZV is more widely implicated
in the pathogenesis of cerebrovascular disease, although
precise biological mechanisms remain unclear.
In general, there has been very little research aimed at
characterising the major risk factors for stroke in Africa,
but the burden of disease appears to be similar to that in
the UK [9–12]. We therefore conducted a pilot study
nested within a long-standing rural population cohort in
Uganda, to investigate whether the pattern of VZV anti-
bodies differed over time in individuals who subsequently
develop stroke vs. those who did not.
Methods
This pilot case–control study of stroke in relation to
VZV was conducted within the context of an existing
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population-based cohort study – the General Population
Cohort (GPC). The GPC was originally established in
1989, by the UK Medical Research Council (MRC) and
the Uganda Virus Research Institute (UVRI), in Kalungu
District (at that time in Masaka District), south-western
Uganda, to examine prevalence, incidence, risk factors
and trends of infection with the human immunodeficiency
virus (HIV) in a rural African population [13]. More
recently, research activity has broadened to include the
epidemiology and genetics of other communicable and of
non-communicable diseases (NCDs), including cancer,
cardiovascular disease and diabetes [14].
In brief, the GPC is a community-based open cohort
study of residents of neighbouring villages within one
half of a subcounty, lying about 40 km from the shores
of Lake Victoria. The population is scattered across the
countryside in villages defined by administrative bound-
aries with a few concentrated in small trading centres.
Agriculture is the main economic activity with rain-fed,
small-holder farms. A population of approximately
10 000 people in a cluster of 15 villages was studied
from 1989 to 1999. In 2000, the GPC was expanded to
cover a further 10 villages. The cohort is dynamic; new
births, deaths and migration are reported at each round
of follow-up, and the population under survey currently
includes approximately 22 000 people. Data are collected
through an annual census, questionnaire and serological
survey. Details of sexual behaviour, medical, socio-
demographic and geographic factors are recorded. Blood
specimens are obtained at each survey. Serum is tested
for HIV-1, and the remainder is stored at 80 °C in
freezers in Entebbe. Seroprevalence of HIV initially
declined from 8.9% in 1991 to 6.2% in 2001 and later
increased to 10% in 2012 [14].
For the purposes of this pilot study, cases of stroke
were identified in two ways. Firstly, prevalent cases were
identified by the MRC/UVRI GPC Social Science Team
from among GPC participants in and around a single vil-
lage who showed signs of having had a stroke (face
dropped on one side, paralysis, slurred speech). Each
individual was then visited by a clinical team and the
diagnosis of stroke confirmed on the basis of clinical
signs and symptoms; in each case, the stroke had
occurred within the previous 3 years. Thirty-one people
were identified in this way, and of those, 19 had blood
samples available for analysis from prior to the diagnosis.
Secondly, between 2006 and 2008, all deaths occurring
within the GPC were subject to verbal autopsy [15]; for
14 people, the cause of death was listed as stroke, of
whom 12 had available blood samples. No detailed char-
acterisation of the underlying pathology was possible as
CT scan is not available near the study site. From this
point on, data were de-identified and study numbers were
used in all analyses.
Controls were selected from among adults in the same
village without a diagnosis of stroke using the following
procedure: each case was classified by sex and age at the
time of their diagnosis. Potential controls were then
examined to find the time points at which their character-
istics (sex and age) matched those of the case, and this
time point was then taken as the pseudodiagnosis date
for that control. For each case, all matched controls were
selected and included in a data set as matched to the cor-
responding case. At least four controls were then identi-
fied from this database and matched to the case on sex
and age at the time of pseudodiagnosis/death and on
availability of stored blood samples. In this way, 31 clini-
cally confirmed cases were identified and 132 controls.
Each participant had three stored serum samples identi-
fied from the archive: one from the period at or near the
time of (pseudo)diagnosis, one 5–10 years and one at
about 15 years before diagnosis.
The serial serum samples taken prior to the diagnosis/
pseudodiagnosis dates for cases and controls were tested
for antibodies against VZV using standard, well-validated
and commercially available quantitative indirect chemilu-
minescent immunoassays against both IgM and IgG
(Novatec Immundiagnostica GmbH). Testing was
conducted at the Uganda Virus Research Institute in
Entebbe, Uganda, by experienced individuals who were
blind to whether the samples were from a case or a
control. Briefly, serum samples were thawed and diluted
100-fold in sample diluent before dispensing 100 ll of
samples and controls into each well of a 96-well plate
coated with varicella zoster virus (VZV) antigen. Plates
were covered and incubated for 1 h at 37 °C before -
thorough washing. Hundred microlitre of VZV anti-IgM
or IgG was then added and the plate incubated for
30 min at room temperature before washing again.
Hundred microlitre of tetra-methyl-benzidine (TMB)
substrate solution was then added, the plate was incu-
bated for 15 min in the dark at room temperature, and
100 ll of 0.2 M sulphuric acid was added to stop the
reaction. Plates were read at 450 nm to obtain optical
density (OD) – a marker of antibody titre.
The characteristics of cases and of controls were
initially compared using a Mann–Whitney two-sample
test or chi-squared test as appropriate. The changes in
antibodies for both IgG and IgM were analysed using lin-
ear regression adjusted for matching factors age and sex.
Correlation between repeated measurements on individ-
ual patients was adjusted for using generalised estimating
equations (GEE) with an exchangeable correlation struc-
ture. To graphically present trends in OD, the GEE
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model was used to predict mean ODs, linear predictor
and standard errors for both cases and controls from a
population of individuals in a 1:1 sex ratio, with a med-
ian age of 60 years at (pseudo)diagnosis. The model
allowed for interaction between case indicator and years
preceding diagnosis of the case, to assess whether the
effects vary with duration. Tests for statistical significance
were derived from likelihood ratio test statistics. All
P-values are two-sided, and significance was considered
at the 5% level. Analyses were carried out using Stata 12
(StataCorp LP, College Station, TX, USA).
Ethical approval for this study was obtained from the
Uganda Virus Research Institute Science and Ethics Com-
mittee and from the Uganda National Council for Science
and Technology.
Results
Table 1 shows the characteristics of study participants at
the time point closest to (pseudo) diagnosis of stroke. Of
the 31 cases and 132 controls, all had detectable IgG and
IgM antibodies against VZV. There were no statistically
significant differences observed in the optical densities
between cases and controls (Mann–Whitney: IgG,
P = 0.47; IgM, P = 0.69). In relation to HIV, 16% (5/
31) of cases were seropositive compared to 6% (8/132)
of controls (odds ratio (OR) = 3.0; 95% confidence inter-
val (CI) 0.8–10.1; P = 0.06). Of those who were HIV
seropositive, three cases and two controls were on anti-
retroviral therapy at the time of (pseudo)diagnosis.
Figure 1a,b shows the evolution of optical density over
time for IgG and IgM antibodies against VZV, respec-
tively, in the 15-year period prior to (pseudo)diagnosis.
For neither was there any significant difference between
cases and controls or indeed any change over time prior
to (pseudo)diagnosis.
Discussion
This is the first study of VZV in relation to risk of stroke
that assessed exposure using a biological measure – both
Table 1 Characteristics of study participants at the time point
closest to (pseudo)diagnosis of stroke
Factor
Cases
n = 31
Controls
n = 135 P value
Age in years,
mean
(standard
deviation)
59.0 (13.7) 60.2 (13.7) Matching
factor
Sex
Females 15 (48%) 67 (50%) Matching
factor
Males 16 (52%) 68 (50%)
Median
VZV IgG
(Interquartile
range – IQR)
2.06 (1.45–2.42) 1.91 (1.52–2.26) 0.47*
Median VZV
IgM (IQR)
0.32 (0.19–0.43) 0.29 (0.20–0.50) 0.69*
HIV status
Negative 26 (84%) 124 (94%) 0.06†
Positive 5 (16%) 8 (6%)
ART status among HIV+
Not on ART 2 (40%) 6 (75%) 0.21†
On ART 3 (60%) 2 (25%)
*Mann–Whitney two-sample test, †chi-squared test; VZV, vari-
cella zoster virus; ART, antiretroviral therapy; IQR, interquartile
range.
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Figure 1 IgG and IgM antibodies against Varicella Zoster Virus
in the 15 years prior to diagnosis of stroke for cases, or pseudo-
diagnosis (for controls). The red symbols and lines are the stroke
cases and the blue symbols and lines are for controls.
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IgG and IgM antibodies against VZV antigens – and also
the first study from a resource-constrained setting. No
associations were identified. However, as a secondary
finding, the data suggest a threefold excess risk of stroke
in association with HIV infection, based on five HIV-
seropositive cases of 31 and eight of 132 controls; the
finding was of borderline statistical significance
(P = 0.06).
A possible association between VZV and stroke was
first identified in clinical series from western countries, in
which individuals with herpes zoster who subsequently
died of stroke were found to have evidence of VZV vas-
culopathy in the brain, at post-mortem [2, 3]. In the light
of this, a number of very large population-based studies
were conducted in which records of prescription for her-
pes zoster antiviral drugs or of diagnosis of herpes zoster
or chickenpox were linked to records of subsequent
stroke, using national registers or clinical databases [4–
8]. The risk of stroke was highest within 6 months of the
diagnosis of VZV disease (or receipt of antiviral drugs),
declining thereafter and was also highest among people
under the age of 40 years compared to those who were
older. It is difficult in such studies to be sure that any
association is causal, when both diagnoses could be
secondary to some other factor or factors.
A clear strength of this pilot study is the measurement
of antibodies against VZV: IgG is a marker of past
exposure and IgM is thought to indicate more recent
exposure. All participants had antibodies against both
antigens, confirming the ubiquitous nature of infection
with VZV in Uganda. However, given the small size of
the study and the lack of characterisation of stroke
pathology, we cannot completely exclude the possibility
that VZV is a cause of a subset of stroke cases. In addi-
tion, the median age of our participants was 60 years, so
any effect on younger stroke cases could not be exam-
ined. However, given the prospective design of the study,
it would seem unlikely that VZV is a major cause of
stroke in rural Uganda.
The increased risk of stroke in association with HIV
infection, although a secondary finding and based on
small numbers, is of interest. Numerous hospital series of
HIV-infected people and of stroke patients have
suggested a link between HIV and stroke, but there have
been no other prospective studies and few case–control
studies to adequately quantify the excess risk or to
characterise the specific pathologies of stroke in the
context of HIV [16, 17]. There are a number of possible
biological mechanisms whereby both HIV itself and the
antiviral therapies used to treat it might increase the risk
of stroke [18, 19]. The relative importance of these,
however, is unclear.
In summary, in this small pilot study, we find no
evidence to suggest that VZV is a major cause of stroke
in rural Uganda. However, we do provide some evidence
to suggest that infection with HIV may be an important
risk factor. In the future, we plan more thorough identifi-
cation of stroke cases within the entire cohort, with
active case-finding, real-time reporting from local people
who serve the GPC as village birth and death recorders
and use of verbal autopsy to identify those who did not
survive the initial event. It would seem that stroke is
sufficiently common in this population and that over
time, the number of cases we can identify could be more
substantial than we report here.
Acknowledgements
The Ugandan General Population Cohort study is jointly
funded by the UK Medical Research Council (MRC) and
the UK Department for International Development
(DFID) under the MRC/DFID Concordat agreement.
References
1. Arvin A. Varicella-zoster virus. In: Fields BN, Knipe DM
(eds). Virology. Lippincott-Raven: Philadelphia, PA, 1998,
2547–2587.
2. Gilden D, Cohrs RJ, Mahalingam R & Nagel MA. Varicella
zoster virus vasculopathies: diverse clinical manifestations,
laboratory features, pathogenesis and treatment. Lancet
Neurol 2009: 8: 731–740.
3. Gilden D, Lipton HL & Wolf JS. Two patients with unusual
forms of varicella zoster virus vasculopathy. N Engl J Med
2002: 347: 1500–1503.
4. Kang JH, Ho JD, Chen YH & Lin HC. Increased risk of
stroke after a herpes zoster attack: a population-based fol-
low up study. Stroke 2009: 40: 3443–3448.
5. Sreenivasan N, Basit S, Wohlfahrt J et al. The short and
long term risk of stroke after herpes zoster – a nationwide
population-based cohort study. PLoS One 2013: 8: e69156.
6. Breuer J, Pacou M, Gauthier A & Brown MM. Herpes zos-
ter as a risk factor for stroke and TIA. Neurology 2014: 82:
206–212.
7. Langan SM, Minassian C, Smeeth L, Thomas SL. Risk of
stroke following herpes zoster: a self-controlled case-series
study. Clin Infect Dis 2014: 58: 1497–1503.
8. Thomas SL, Minassian C, Ganesan V, Langan SM, Smeeth
L. Chickenpox and risk of stroke: a self-controlled case
series analysis. Clin Infect Dis 2014: 58: 61–68.
9. Walker R, Whiting D, Unwin N et al. Stroke incidence in
rural and urban Tanzania: a prospective, community based
study. Lancet Neurol 2010: 9: 786–792.
10. Walker RW, McLarty DG, Kitange HM et al. Stroke mor-
tality in urban and rural Tanzania. Lancet 2000: 355:
1684–1687.
4 © 2015 John Wiley & Sons Ltd
Tropical Medicine and International Health volume 00 no 00
G. Asiki et al. Pilot study on stroke an VZV
11. Conner MD, Walker R, Modi G, Warlow CP. Burden of
stroke in black populations in sub-Saharan Africa. Lancet
Neurol 2007: 6: 269–278.
12. The SASPI Project Team. Prevalence of stroke survivors in
rural South Africa: results from the Southern Africa Stroke
Prevention Initiative (SASPI) Agincourt Field Site. Stroke
2004: 35: 627–632.
13. Nunn AJ, Kengeya-Kayondo JF, Malamba SS, Seeley JA,
Mulder DW. Risk factors for HIV-1 infection in adults in a
rural Ugandan community: a population study. AIDS 1994:
8: 81–86.
14. Asiki G, Murphy G, Nakiyingi-Miiro J et al. The general
population cohort in rural south-western Uganda: a platform
for communicable and non-communicable disease studies.
Int J Epidemiol 2013: 42: 129–141.
15. Mayanja BN, Baisley K, Nalweyiso N et al. Using verbal
autopsy to assess the prevalence of HIV infection
among deaths in the ART period in rural Uganda: a
prospective cohort study, 2006–2008. Popul Health Metr
2011: 9: 36.
16. Benjamin LA, Bryer A, Emsley HCA, Khoo S, Solomon T,
Connor MD. HIV infection and stroke: current perspectives
and future directions. Lancet Neurol 2012: 11: 878–890.
17. Mochan A, Modi M, Modi G. Stroke in black South African
HIV-positive patients: a prospective analysis. Stroke 2003:
34: 10–15.
18. Mochan A, Modi M, Modi G. Protein S deficiency in HIV
associated ischaemic stroke: an epiphenomenon of HIV
infection. J Neurol Neurosurg Psychiatry 2005: 76:
1455–1456.
19. Ortiz G, Koch S, Romano JG, Forteza AM, Rabinstein AA.
Mechanisms of ischaemic stroke in HIV–infected patients.
Neurology 2007: 68: 1257–1261.
Corresponding Author Robert Newton, MRC/UVRI Research Unit on AIDS, P.O. Box 49, Entebbe, Uganda.
E-mails: Rob.Newton@mrcuganda.org, Rob.Newton@ecsg.york.ac.uk
© 2015 John Wiley & Sons Ltd 5
Tropical Medicine and International Health volume 00 no 00
G. Asiki et al. Pilot study on stroke an VZV
